PAO Group, Inc. (USOTC: PAOG) today announced Goldman Small Cap Research has published an initial analyst report covering PAOG’s outlook following two recent acquisitions moving the company into the cannabis biopharma market sector. The report highlights that recent acquisitions have repositioned PAOG for growth in a sector with market cap valuations as high as $100 million. As an example, to illustrate PAOG’s potential for an increased market cap, the report compares PAOG to another OTC company in the cannabis biopharma sector with a market capitalization five times PAOG’s current valuation.
“Via its recent acquisitions, PAOG has re-positioned itself as an emerging CBD Biopharma company on a development path to treat two major respiratory diseases that each represent billions in potential market sizes.”
“Leveraging a series of favorable studies, the Company is set to engage a CRO to initiate the process for potential FDA approval of RespRx, its new flagship COPD treatment. COPD represents an estimated $14.1B market by 2025.”
“After completing a recent 25 patient study using RespRx to treat COVID-19 symptoms, PAOG is preparing to commence a similar development pathway for this disease.”
“Now that the key acquisitions have been closed, management is preparing to complete corporate, capital markets, and investor relations housekeeping tasks to ensure investors have access to the most recent company financial statements and reports.”
“We should note that a number of CBD Biopharma companies are publicly traded, with market caps ranging as high as $100M or more. Based on our cursory due diligence we found one firm, Avianna (OTC – AVCNF – NR), which is also targeting the COVID-19 arena, that has a current market cap of around $27M. Perhaps as PAOG moves along the development path on either the COPD or COVID-19 track, it can trade toward this figure, assuming current financials and information are available.”
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.